Thirty-Ninth Board Meeting

<p>Tamaki Tsukada from the Japan constituency is designated as Rapporteur for the 39th Board Meeting.</p>

<p>The agenda for the 39th Board Meeting (GF/B39/01 – Revision 2) is approved.</p>

<ol> <li>Based on the recommendation of the Strategy Committee, the Board approves the revised Eligibility Policy, as set forth in Annex 1 to GF/B39/02 (the “Revised Eligibility Policy”).</li> <li>Accordingly, the Board: <ol type="i"> <li>Acknowledges that this decision point and the Revised Eligibility Policy supersede the decision point GF/B35/DP07 and the previous Eligibility Policy as set forth in Annex 2 to GF/B35/06 - Revision 1 (the “Previous Eligibility Policy”); and</li> <li>Notes that notwithstanding paragraph 2.i of this decision point, the Previous Eligibility Policy remains applicable to grant programs originating from the 2017-2019 allocation period.</li> </ol> </li> </ol>

<ol> <li>The Board acknowledges that a health crisis may emerge in an ineligible non-high income country that could have an adverse impact on the global response against HIV/AIDS, tuberculosis, and/or malaria, and that the health crisis may be of such a magnitude that the Global Fund should consider providing support; and</li> <li>Based on the recommendation of the Strategy Committee, the Board requests the Secretariat, in consultation with relevant partners, to present potential investment cases meeting the criteria described in GF/B39/03 – Revision 1 to the Strategy Committee for review and recommendation to the Board. Any such proposals shall also include options for how the proposed investment should be funded.</li> </ol>

<ol> <li>The Board approves the appointment of the following individuals to serve as voting members of the Audit and Finance Committee, representing the Board constituency listed by their name:<br /> <ol type="i"> <li>Pasqualino Procacci, European Commission, Belgium, Italy, Portugal, Spain;</li> <li>Greg Ferrante, Private Foundations;</li> <li>Michael Ruffner, United States;</li> <li>Chris Taylor, United Kingdom;</li> <li>Gilles Angles, France;</li> <li>Maurine Murenga, Communities;</li> <li>Allan Maleche, Developing Country NGOs;</li> <li>Naveed Kamran Baloch, Eastern Mediterranean Region;</li> <li>Guillermo Birmingham, Latin America and the Caribbean; and</li> <li>Sukhbir Singh, South East Asia.<br /><br />The Board appoints the following individuals to serve as non-voting members of the Audit and Finance Committee, representing the Board constituency listed by their name:<br /><br /></li> <li>Iris Semini, UNAIDS; and</li> <li>Alexandru Cebotari, World Bank.<br /><br /></li> </ol> </li> <li>The Board approves the appointment of the following individuals to serve in their personal capacity as voting members of the Ethics and Governance Committee:<br /> <ol type="i"> <li>Suomi Sakai, Japan;</li> <li>Anders Nordström, Point Seven;</li> <li>Renuka Gadde, Private Sector;</li> <li>David Kihumuro Apuuli, Eastern and Southern Africa;</li> <li>Ana Filipovska, Eastern Europe and Central Asia; and</li> <li>Mohamed Chakroun, Eastern Mediterranean Region.<br /><br /></li> </ol> </li> <li>The Board approves the appointment of the following individuals to serve as voting members of the Strategy Committee, representing the Board constituency listed by their name:<br /> <ol type="i"> <li>Timothy Poletti, Canada, Switzerland and Australia;</li> <li>Jean-François Pactet, France;</li> <li>Heiko Warnken, Germany;</li> <li>Sarah Boulton, United Kingdom;</li> <li>Mamadi Yilla, United States;</li> <li>Mike Podmore, Developed Country NGOs;</li> <li>Nduku Kilonzo, Eastern and Southern Africa;</li> <li>Violeta Teutu, Eastern Europe and Central Asia;</li> <li>Abdoulaye Ciré Anne, West and Central Africa; and,</li> <li>Ingrid Glastonbury, Western Pacific Region.<br /><br />Noting that the Chairs of the Technical Review Panel and the Technical Evaluation Reference Group serve as non-voting members of the Strategy Committee, the Board appoints the following individuals to serve as additional non-voting members of the Strategy Committee:<br /><br /></li> <li>Lucica Ditiu, Partners (Stop TB); and</li> <li>Mubashar Sheikh, World Health Organization.<br /><br /></li> </ol> </li> <li>The Board approves the renewal for one additional term of:<br /> <ol type="i"> <li>Jean-Michel Ferat as Independent Member of the Audit and Finance Committee with forensic investigation expertise;</li> <li>Peter Maertens Independent Member of the Audit and Finance Committee with financial audit expertise; and</li> <li>Joan Elise Dubinsky as Independent Member of the Ethics and Governance Committee with ethics expertise.<br /><br /></li> </ol> </li> <li>The Board notes each of the individuals appointed under this decision point shall begin his/her term on 11 May 2018 and serve for two years or until the appointment of his/her successor.</li> </ol>

<ol> <li>Notes its commitment to continue to strengthen Global Fund governance processes and requests that the Ethics and Governance Committee (“EGC”) undertakes a review of the existing processes for selection of committee leadership and members, and makes recommendations to the Board on revisions to these selection processes, aiming for a decision at the 40th Board Meeting;</li> <li>Requests that as part of this recommendation, the EGC (i) puts forward principles and concrete actions to underpin and guide the selection processes, including transparency, rotation of constituency representation, relevant experience, institutional memory, and gender equality; (ii) develops standards and processes for due diligence undertaken as part of the selection processes; and (iii) reviews the size and composition of the EGC; and</li> <li>Requests that the EGC seeks feedback broadly from across Board constituencies in formulating its recommendations, including through inviting a representative of civil society to be a participant in EGC deliberations on this review.</li> </ol>

<p>The Board authorizes the issuance of, and therefore ap proves, the Global Fund’s 2017 Annual Financial Report, which includes the 2017 Consolidated Financial Statements that have been audited by KPMG SA, as set forth in GF/B39/06 Annex 1.</p>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2017 Statutory Financial Statements, which have been audited by KPMG SA, as set forth in GF/B39/06 Annex 2.</p>

<p>The Board:</p> <ol> <li>Notes the recommendation of the Ethics and Governance Committee of a Code of Conduct for Country Coordinating Mechanisms (the “CCM Code”), developed in furtherance of the Ethics and Integrity Framework adopted by the Board at its 32nd Meeting (GF/B32/DP09);</li> <li>Approves the CCM Code, as presented in Annex 4 in GF/B39/04- Revision 1;</li> <li>Based on the recommendation of the Strategy Committee (“SC”), decides that no less than the amount of USD 1,219,700 should be made available over a three year period to fund the implementation and enforcement of the CCM Code, as described in GF/B39/04- Revision 1;</li> <li>Recognizes that the Audit and Finance Committee approved USD 50 million as available sources of funds (“Available Funds”) to finance prioritized and costed areas of need on the register of unfunded quality demand, as per GF/AFC04/DP01, and based on the recommendation of the SC, (i) decides that the amount of USD 1,219,700 of such Available Funds be used instead to fund the implementation and enforcement<br />of the CCM Code, and (ii) decides to add CCMs as a “Strategic Initiative” to the list of catalytic investment priorities presented in Table 1 of GF/B36/04 – Revision 2;</li> <li>Based on the recommendation of the SC, decides to replace the Guidelines and Requirements for Country Coordinating Mechanisms, as approved by the Board under GF/B23/DP17, with the CCM Policy as set out in Annex 3 of GF/B39/04- Revision 1 (the “CCM Policy”); and</li> <li>Delegates authority to the SC to approve amendments to the CCM Policy, and requests the Secretariat to operationalize the CCM Policy and regularly report on its implementation to the SC.</li> </ol>

<p>The Board:</p> <ol> <li>Recognizes the inherent value and essential function of Country Coordinating Mechanisms (“CCMs”) in the Global Fund architecture and acknowledges the need to evolve CCMs to align with the Global Fund Strategy 2017-2022: Investing to End Epidemics;</li> <li>Recognizes that the Audit and Finance Committee approved USD 50 million as available sources of funds (“Available Funds”) to finance prioritized and costed areas of need on the register of unfunded quality demand, as per GF/AFC04/DP01;</li> <li>Based on the recommendation of the Strategy Committee (“SC”), decides that the amount of USD 3.85 million of such Available Funds be used instead to fund a phased roll-out of the evolution of Country Coordinating Mechanisms (the “CCM Evolution”) in 2018 and 2019 under the CCM Strategic Initiative, consistent with the interventions and activities under the “intermediate” approach, as detailed in GF/B39/04 – Revision 1;</li> <li>Requests the Secretariat (1) to develop a set of draft indicators for consultation with the SC at its July 2018 meeting, including near term (process and output) and longer term (outcome and impact) indicators, and (2) to regularly report to the SC on the operationalization of the CCM Evolution;</li> <li>Directs the SC (1) to utilize the near term results (referenced in part 4 above) as one of the inputs to inform the type of activities and the level of funding for CCM Evolution in the 2020-2022 allocation period, and (2) during the development of the allocation methodology for this period, to discuss the level of funding needed to scale the activities and number of CCMs; and</li> <li>Asks the Board, Secretariat and partners at country level to support the effective implementation of CCM Evolution, and in particular asks the Secretariat to drive the execution of CCM Evolution through consistent engagement of relevant parts of the organization and with an appropriate mix of resources, both staff and financial, from both current and future allocations.</li> </ol>

<p>The Board:</p> <ol type="i"> <li>Acknowledges the decision of the Strategy Committee concurring with the Risk Appetite Statements for the risks under such committee’s purview, as set forth in the table in Annex 3 to GF/SC06/03 – Revision 2;</li> <li>Acknowledges that the Strategy Committee will further discuss the Human Rights and Gender Inequality, Transition, and Drug and Insecticide Resistance risks at its meeting in July 2018, which will include discussion of the risk management strategy for these risks, including mitigation measures in place and/or planned, and a determination of the appropriateness of setting risk appetite statements for these risks;</li> <li>Further acknowledges the decision of the Audit and Finance Committee concurring with the Risk Appetite Statements for the risks under such committee’s purview, as set forth in the table in Annex 3 to GF/AFC06/16 – Revision 1; and</li> <li>Based upon the recommendation of the Audit and Finance Committee, approves the Risk Appetite Framework, including Risk Appetite, Target Risk levels and the indicative timeframes for achieving Target Risk, as described in the table in Annex 3 to GF/B39/07.</li> </ol>

<ol> <li>The Board notes the recommendation of the Ethics and Governance Committee (the “EGC”), as set forth in GF/B39/05 – Revision 1, and acknowledges the need to strengthen the current process for selecting the Chair and Vice-Chair of the Board.</li> <li>Based on the recommendation of the EGC, the Board approves, in principle, the revised process for selecting the Chair and Vice-Chair of the Board as detailed in Section II of GF/B39/05- Revision 1 (the “Revised Board Leadership Selection Process”) and the Draft Terms of Reference of the Board Leadership Nomination Committee (the “BLNC ToRs”) as provided for in Annex 7 of GF/B39/05 – Revision 1.</li> <li>The Board requests the Secretariat to finalize the BLNC ToRs and to prepare the necessary revisions to the core governance documents to implement the Revised Board Leadership Selection Process for review by the EGC and recommendation to the Board for approval ahead of the planned 2018 launch of the call for nominations for Board Chair and Vice-Chair.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b to GF/B39/EDP01 (“Table 1a” and “Table 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a and Table 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<ol> <li>The Board: <ol type="i"> <li>Recalls its decision (GF/B38/DP05) on the Integration of Additional Public Donors into the Global Fund Governance Structure and Amendment of the Global Fund Bylaws;</li> <li>Notes the requirement of the Operating Procedures of the Board and Committees pursuant to which each constituency of the Board must be represented in at least one Standing Committee of the Board; and</li> <li>iii. Notes the recommendation of the Ethics and Governance Committee, as set forth in GF/B39/ER02, to create an additional non-voting committee seat within the Strategy Committee.</li> </ol> </li> </ol> <ol start="2"> <li>Accordingly, the Board approves the creation of an additional non-voting seat in the Strategy Committee and, to this effect, amends Section C., article 3, paragraph e. of the Charter of the Strategy Committee, as set forth in Annex 1 to GF/B39/ER02.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b to GF/B39/EDP03 (“Table 1a” and “Table 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a and Table 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>Based on the recommendation of the Board Chair and Vice-Chair, the Board:</p> <ol> <li>Expresses its appreciation for the work done by the members of the PIAG.</li> <li>Approves the amended terms of reference of the PIAG as set out in Annex 2 to GF/B39/ER04</li> <li>Decides to renew the term of the PIAG for an additional period of three years starting at the conclusion of the 39th Board Meeting and ending on 10 May 2021.</li> <li>Requests the Ethics and Governance Committee to select and appoint the members of the PIAG and to inform the Board of the outcome of the selection process.</li> </ol>

<p>1. The Board approves the appointment of Ambassador Stephanie Seydoux, representing the French Constituency, as a voting member of the Strategy Committee (“SC”) for a term that will expire in May 2020, or until the appointment of her successor.</p>

<p>The Board approves the Report of the 39th Board Meeting, as set forth in GF/B39/26 – Revision 2.</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b to GF/B39/EDP07 (“Table 1a” and “Table 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a and Table 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<ol> <li>The Board recalls its decision GF/B39/DP12 on the strengthening of the Board Leadership selection process.</li> <li>Based on the recommendation of the Ethics and Governance Committee, the Board approves the Terms of Reference of the Board Leadership Nomination Committee and the corresponding amendments to the Operating Procedures of the Board and Committees of the Global Fund and the Charter of the Ethics and Governance Committee as provided for in Annexes 4, 5, and 6 of GF/B39/ER07.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b to GF/B39/EDP09 (“Table 1a” and “Table 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a and Table 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<ol> <li>The Board: <ol type="i"> <li>Recalls its decision (GF/B38/DP05) on the Integration of Additional Public Donors into the Global Fund Governance Structure and Amendment of the Global Fund Bylaws;</li> <li>Notes the requirement of the Operating Procedures of the Board and Committees pursuant to which each constituency of the Board must be represented in at least one Standing Committee of the Board;</li> <li>Notes the Board decision (GF/B39/EDP02) to create an additional non-voting committee seat within the Strategy Committee; and</li> <li>Notes that the Additional Public Donors Constituency is not currently represented on a Standing Committee of the Board.</li> </ol> </li> </ol> <ol start="2"> <li>Accordingly, the Board appoints Kaltham Al-Assam, representing the Additional Public Donors Constituency, as a non-voting member of the Strategy Committee for a term that will expire in May 2020, or until the appointment of her successor.</li> </ol>

<p>The Board:</p> <ol> <li>Expresses continuing concern about the public health crisis in Venezuela, a country that is not currently eligible for Global Fund funding, and its adverse impact on the fight against HIV, tuberculosis and malaria in Venezuela and the region;</li> <li>Acknowledges the extraordinary proposal for funding presented by the Secretariat, and developed in consultation with partners and civil society, in accordance with the approach for potential engagement with non-eligible countries in crisis approved by the Board through GF/B39/DP04;</li> <li>Recognizes that the emergency circumstances in Venezuela and the exceptional nature of the funding proposed require unique implementation and management arrangements, which differ substantially from the standard Global Fund funding model and applicable policies, as described in Annex 1 to GF/B39/ER10 (Annex 1);</li> <li>Accepts that the proposed implementation and management arrangements entail unique risks, as described in GF/B39/ER10 and Annex 1, including that the Office of the Inspector General will not be able to provide the Board with assurance, whether through audit or investigation work, over the funds disbursed under the proposed funding arrangements;</li> <li>Based on the recommendation of the Strategy Committee, approves the investment and terms set forth in Annex 1, to provide USD 5,000,000 to support the procurement of critical health products for Venezuela; and</li> <li>Calls for continuous engagement from relevant partners, donors and other stakeholders to further support a regional response to the health crisis in Venezuela.</li> </ol>

<ol> <li>The Board hereby delegates to each of the Chair and Vice-Chair of the Board and the Executive Director, individual signature authority on behalf of the Global Fund.</li> <li>The Board hereby authorizes the Executive Director to: <ol type="i"> <li>further delegate his signature authority to Secretariat staff, who may exercise such authority in sole or joint capacities as may be necessary and appropriate for the day-to-day management of the operations of the Global Fund under the direction of the Executive Director and in accordance with the applicable regulations of the Global Fund; and</li> <li>memorialize such delegations of signature authority and any limitations or conditions applicable thereto in proxies and/or signature authority regulations.</li> </ol> </li> <li>The Board hereby affirms the further delegation of individual signature authority, in accordance with the Executive Director’s issuance of proxies and/or signature authority regulations, to each of the Chief of Staff and the Chief Financial Officer of the Global Fund.</li> <li>This decision supersedes the Board’s delegation of signature authority contained in Decision Point GF/B19/DP23 (May 2009).</li> </ol>

<p>The Board hereby notes the Executive Director’s appointment of the following senior management officials of the Global Fund:</p> <ol type="i"> <li>Marijke Wijnroks, as Chief of Staff, and</li> <li>Jacques Le Pape, as Chief Financial Officer.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b to GF/B39/ER12 (“Table 1a” and “Table 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a and Table 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Notes the Secretariat’s review of the items on the 2017- 2019 allocation period’s register of Unfunded Quality Demand (“UQD”) in accordance with the prioritization framework approved by the Strategy Committee through GF/SC04/DP02;</li> <li>Approves the additional incremental funding recommended for certain UQD of the following country disease components: (i) Burundi Malaria, and (ii) Philippines TB, as listed in Table 2 of GF/B39/ER12, based on available funding approved by the Audit and Finance Committee;</li> <li>Affirms the additional incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<ol> <li>The Board notes the recommendation of the Ethics and Governance Committee, as set forth in GF/B39/ER13, relating to the membership of the Board Leadership Nomination Committee (“Nomination Committee”).</li> <li>Accordingly, the Board appoints the following individuals to serve as members of the Nomination Committee in accordance with the terms of reference of the Nomination Committee approved under electronic decision point GF/B39/EDP08 and set out in Annex 4 to GF/B39/ER07:<br /> <ol type="a">a. Stéphanie Seydoux, Chair of the Nomination Committee;</ol> <ol type="a">b. Vikas Sheel, Vice-Chair of the Nomination Committee;</ol> <ol type="a">c. Paul Schaper, Member;</ol> <ol type="a">d. Rachel Ong, Member;</ol> <ol type="a">e. Sherwin Charles, Member;</ol> <ol type="a">f. Olaitan Tajudeen Ibrahim; Member and,</ol> <ol type="a">g. Minghui Ren, Member.</ol> </li> </ol>

<ol> <li>Based on the recommendation of the Audit and Finance Committee, the Board approves the 2019 performance target of USD 115 million for Key Performance Indicator 12b as presented in GF/B39/ER14A.</li> </ol>

<ol> <li><span>The Board approves the revised Terms of Reference of the Chair and Vice-Chair of the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria, as revised and set forth in Annex 1 to GF/B39/ER15 (the “Terms of Reference”), which shall enter into force upon the commencement of the term of the next Chair and Vice-Chair of the Board.</span></li> <li><span>The Terms of Reference shall supersede any and all prior versions of terms of reference of the Board Chair and Vice-Chair previously approved by the Board.</span></li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Table 1 to GF/B39/ER16 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Notes the Secretariat’s review of the items on the 2017- 2019 allocation period’s register of Unfunded Quality Demand (“UQD”) in accordance with the prioritization framework approved by the Strategy Committee through GF/SC04/DP02;</li> <li>Approves the additional incremental funding recommended for certain UQD of the following country disease component: (i) Rwanda malaria, as listed in Table 2 of GF/B39/ER16, based on available funding approved by the Audit and Finance Committee;</li> <li>Affirms the additional incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>